Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Profit After Tax (2016 - 2026)

Ovid Therapeutics filings provide 11 years of Profit After Tax readings, the most recent being -$17.0 million for Q1 2026.

  • Quarterly Profit After Tax fell 66.1% to -$17.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$24.1 million through Mar 2026, up 3.33% year-over-year, with the annual reading at -$17.4 million for FY2025, 34.17% up from the prior year.
  • Profit After Tax hit -$17.0 million in Q1 2026 for Ovid Therapeutics, down from $9.7 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $9.7 million in Q4 2025 and bottomed at -$17.0 million in Q1 2026.
  • Average Profit After Tax over 5 years is -$9.8 million, with a median of -$12.0 million recorded in 2022.
  • Peak annual rise in Profit After Tax hit 204.83% in 2025, while the deepest fall reached 154.97% in 2025.
  • Ovid Therapeutics' Profit After Tax stood at -$11.5 million in 2022, then plummeted by 33.18% to -$15.3 million in 2023, then skyrocketed by 39.61% to -$9.3 million in 2024, then skyrocketed by 204.83% to $9.7 million in 2025, then plummeted by 275.26% to -$17.0 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Profit After Tax are -$17.0 million (Q1 2026), $9.7 million (Q4 2025), and -$12.2 million (Q3 2025).